207 related articles for article (PubMed ID: 20670950)
1. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
Mizutani T; Kondo T; Darmanin S; Tsuda M; Tanaka S; Tobiume M; Asaka M; Ohba Y
Clin Cancer Res; 2010 Aug; 16(15):3964-75. PubMed ID: 20670950
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
3. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
Desplat V; Lagarde V; Belloc F; Chollet C; Leguay T; Pasquet JM; Praloran V; Mahon FX
Cytometry A; 2004 Nov; 62(1):35-45. PubMed ID: 15468123
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib].
Xu N; Ouyang Z; DU QF; Wang S; Yang J; Wang Y; Liu XL
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):25-8. PubMed ID: 21429397
[TBL] [Abstract][Full Text] [Related]
5. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
6. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
White D; Saunders V; Grigg A; Arthur C; Filshie R; Leahy MF; Lynch K; To LB; Hughes T
J Clin Oncol; 2007 Oct; 25(28):4445-51. PubMed ID: 17906206
[TBL] [Abstract][Full Text] [Related]
7. Improved FRET Biosensor for the Measurement of BCR-ABL Activity in Chronic Myeloid Leukemia Cells.
Horiguchi M; Fujioka M; Kondo T; Fujioka Y; Li X; Horiuchi K; O Satoh A; Nepal P; Nishide S; Nanbo A; Teshima T; Ohba Y
Cell Struct Funct; 2017 Feb; 42(1):15-26. PubMed ID: 27928132
[TBL] [Abstract][Full Text] [Related]
8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
9. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
10. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
[TBL] [Abstract][Full Text] [Related]
12. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
13. SH2 Domain-Based FRET Biosensor for Measuring BCR-ABL Activity in Living CML Cells.
Fujioka M; Asano Y; Nakada S; Ohba Y
Methods Mol Biol; 2017; 1555():513-534. PubMed ID: 28092053
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
Jiang X; Zhao Y; Smith C; Gasparetto M; Turhan A; Eaves A; Eaves C
Leukemia; 2007 May; 21(5):926-35. PubMed ID: 17330101
[TBL] [Abstract][Full Text] [Related]
15. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
16. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
17. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
18. Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.
Patel H; Marley SB; Greener L; Gordon MY
Leukemia; 2008 Mar; 22(3):559-71. PubMed ID: 18059481
[TBL] [Abstract][Full Text] [Related]
19. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
20. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.
Cang S; Liu D
J Hematol Oncol; 2008 Oct; 1():15. PubMed ID: 18828913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]